rediff News http://www.rediff.com/tags/novartis+ag India's largest news and entertainment service online.. en-us Fri, 09 Dec 16 00:25:42 +0000 Fri, 09 Dec 16 00:25:42 +0000 http://www.rediff.com/push Rediff feeds Copyright: (C) 2009 Rediff.com India Limited. All Rights Reserved. <![CDATA[US warns Novartis on manufacturing violations at 2 India plants]]> http://www.rediff.com/money/report/us-warns-novartis-on-manufacturing-violations-at-2-india-plants-/20151028.htm Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Court bars Cipla from selling copy of Novartis respiratory drug]]> http://www.rediff.com/money/report/court-bars-cipla-from-selling-copy-of-novartis-respiratory-drug/20150113.htm Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Novartis sues Cipla over respiratory drug Onbrez]]> http://www.rediff.com/money/report/novartis-sues-cipla-over-respiratory-drug-onbrez/20141217.htm Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Govt refutes Novartis' allegations on patents]]> http://www.rediff.com/money/report/govt-refutes-novartis-allegations-on-patents/20130828.htm Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[US sues Novartis, alleging kickbacks to pharmacies]]> http://www.rediff.com/money/report/us-sues-novartis-alleging-kickbacks-to-pharmacies/20130425.htm Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[ Grand View Research, Inc.]]> http://in.advfn.com/news_Immunomodulators-Market-Size-to-Reach-USD-233-7-Bi_73092411.html Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC]]> https://www.asianhhm.com/prnews/novartis-announces-zykadia-first-line-study-results-showing-16-6-month-progression-free-survival-in-patients-with-alk-advanced-nsclc Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Dry Powder Inhaler Devices Medical Devices Pipeline Assessment, 2016]]> http://pressreleaseping.com/pressrelease/219097.html Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Novartis' drug tops chemotherapy in untreated lung cancer patients]]> http://feeds.reuters.com/~r/reuters/INhealth/~3/x4wiD4qYbKE/us-novartis-study-idINKBN13V1MF Fri, 09 Dec 2016 05:55:42 +0530 <![CDATA[Novartis data shows Treatmentfree Remission rates are consistently above 50 regardless of reason for switch to Tasigna from Gleevec]]> https://www.pharmafocusasia.com/pressreleases/novartis-data-shows-treatment-free-remission-rates-are-consistently-above-50-regardless-of-reason-for-switch-to-tasigna-from-gleevec Fri, 09 Dec 2016 05:55:42 +0530